Unigene Laboratories, Inc. In-Licenses Potential Therapies for Inflammation and Cardiovascular Disease from University of London

FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) has acquired exclusive commercial rights to a combination therapy with potential value in the treatment of certain inflammatory diseases, and a novel peptide that may find application in the treatment of certain cardiovascular diseases. These rights were acquired from Queen Mary, University of London. The conditions targeted by the inventions include osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, and cardiac reperfusion (restoration of blood flow) injury in heart attack and stroke.